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1 Abbreviations
SEPT6 Septin 6
HCC Hepatocellular carcinoma
qRT-PCR Quantitative real-time PCR
WB Western blot
IHC Immunohistochemistry
PVDF Polyvinylidene difluoride
BSA Bovine serum albumin
CCK-8 Cell Counting Kit-8
PI Propidiumiodide
GEPIA Gene Expression Profiling Interactive Analysis
MMP Matrix metalloproteinase
CCND1 Cyclin D1
LATS1 Large Tumor Suppressor Kinase 1
YAP Yes-associated protein
TEAD TEA domain family member
CLD Chronic liver disease
HSC Hepatic stellate cells
KC Kupffer cell
CRP C-reactive protein
TMC THP-1 macrophage
PAMP Pathogen-associated molecular pattern
PMA Phorbol myristate acetate
SBP Spontaneous bacterial peritonitis
SEC Sinusoidal endothelial cells
E.coli Escherichia coli
E. Cloacae Enterobacter cloacae
E. Faecium Enterococcus faecium
S. Pneumoniae Streptococcus pneumoniae
LDH Lactate dehydrogenase
Myd88 Myeloid differentiation factor 88
MAPK Mitogen-associated protein kinase
NF-κB Nuclear factor-kappa B
IRAK-1 Interleukin receptor- associated kinase-1
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4 Introduction
4.1 An overview of HCC
The heterogeneous disease Hepatocellular carcinoma (HCC) has shown an increasing
incidence and fatality rate, it is a widely common malignance and the third primary
cause of the cancer-related deaths across the globe [1]. And just recently, the HCC
incidence rate approached its fatality rate which is due to the direct relationship
between chronic inflammation, chronic viral infection, hepatocellular carcinoma and
hepatotoxins. Around one million patients die every year due to this disease around
the world. additionally, less than half of the patients (40%) are diagnosed in its early
stages [2], where they reach the point where surgeries are no longer viable, while both
the chemotherapy and the radiotherapy do not exhibit potency against HCC [3] .The
poor prognosis with overall survival rates of 3-5% is mainly due to the distant
metastasis, so it must be significant to pinpoint the foreboding HCC biomarkers.
There has been a significant advancement in identifying and curing HCC over the past
few years. With the systemic therapies being the foundation of the advanced stage
patients treatment.
4.2 Septin family
Septin family, a gene family with GTPase activity in all eukaryotes except plants[4].
Mostowy et al. found that the protein members encoded by the genes of this family
are huge.As a scaffold for protein interactions, septins participate in a series of
important biological behaviors and physiological processes such as the regulation of
cell cycle progression, apoptosis, and cell polarization. More and more evidence
shows that the septin family is closely related to the development of some malignant
tumors and neurodegenerative diseases like leukemia, Parkinson's disease,
Alzheimer's disease, prostate and colorectal cancers.
The microfilaments formed by the septin protein complex serve as scaffolds to recruit
and activate other proteins. Through their scaffolding, they also become important
constituents of membrane-associated proteins. The complex signaling pathways of
various gene proteins between the septin family make more and more people believe
that septins may become a new target in anti-cancer treatment strategies [5]. Therefore,
it is of great significance to focus on the relationship between the molecular and
cellular pathophysiological mechanisms of septins’ influence in cancer or other
diseases.
4.3 Septin structure
A total of 13 human septin proteins have been discovered so far, and they could be
split to 4 classes based on the affinity of their genetic structure [6]. The protein
encoded by the septin gene family has a molecular mass of approximately 39 to 60
kDa [7]. Septins can be oligomerized into repetitive and ordered octamers or
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hexamers that could form more developed structures, including loops or
microfilaments. Septins are rod-shaped and filament-like, which is related to
membranes, actin or microtubules (MTs), so it is therefore regarded to be the fourth
component of the cytoskeleton [8]. According to the degree of sequence similarity,
SEPT gene family members are divided into four different subfamilies. They are
SEPT 2 subfamily (SEPT 1, 2, 4, 5), SEPT 3 subfamily (SEPT 3, 9, 12), SEPT 6
subfamily (SEPT 6, 8, 10, 11, 14) and SEPT 7 subfamily Family (SEPT 7, 13) [9].
4.4 Septin and biology behavior
4.4.1 Septin and mitosis
Through the formation of highly ordered loops at cell division sites, we found that
septins play a significant part in the time-structure yeast germination control [9]. In
mammalian cells, the septins are also considered to be one of the factors that
contribute to mitosis. In fact, after the mediated Cdk1 phosphorylation, the long
SEPT9 subtype becomes a medium for prolyl isomerase Pin1, and in order to achieve
the cytokinesis its isomerization is a must [10]. similar to the Pin1 controlled other
tumor suppressors and oncogenes, specific SEPT9 subtypes may be involved in
tumorigenesis. In addition, Spiliotis et al. found that septins help to achieve correct
chromosome expression and separation in the later stage. Thus, the SEPT2/6/7
complex is deemed crucial for the CENP-E recruitment, a protein that belongs to the
family of kinesin involved in the end stage of mitosis [10].
At the end of mitosis, septins are concentrated in the central spindle area, and interacts
with the actin contractile ring through the partnering protein aniline. Current data
showed that the anillin-septin loop prompts the invasion, narrowing and elongation of
intercellular bridges [11]. Recent research reported on the chrysotile asbestos fibers
consequences (causing mesothelioma, asbestos and lung cancer) have highlighted that
due to over-expression of SEPT2 and the occurrence of formaldehyde and SEPT9
dislocation, this is very common in cancer cells [12].
4.4.2 Septin and membrane structure
Through diffusion in the plasma membrane, septins self-assemble into a microtubule
microfilament structure[13]. Therefore, large-scale septin microfilament arrays that
interact stably with the plasma membrane can change the occurrence of cortical
morphology by applying membrane curvature and affecting migrating cells’ hardness,
thereby contributing to tumor metastasis [14].
In addition, septins are also involved in growth factor receptors associated with cancer
development dysregulation. They could aggregate and balance the proteins of the
plasma membrane, including receptor tyrosine kinases[15]. In fact, the
membrane-associated SEPT9 can prevent the binding of CIN85 to the ubiquitin ligase
Cbl, leading to a reduction in ubiquitin-dependent degradation of EGFR [16]. In
11
addition, septins can persist on the cancer cells plasma membranes by reducing
ubiquitination and degrading ErbB2. Furthermore, the c-Met proto-oncogene surface
distribution is monitored by SEPT2 and 11 in the opposite manner, while both engage
in its interplay with ligands and anchor to the cytoskeleton of actin, elucidating the
subunits composed of septin microfilament can control the importance of biological
functions [17].
4.4.3 Septin and actin
The structure of septin microfilament binds to the cortical area of actin in many cells.
The loss of actin causes septin to form free cytoplasmic loops [18]. In contrast, the
loss of SEPT2 weakens actin binding and destroys stress fibers. Knocking out SEPT6
and SEPT7 can produce similar actin bundle loss and destruction of polarity of the
cells [19]. These ramifications can include septin binding partners that cross-link
septin to actin, such as two of BORG2 and B5 of the five Cdc42 effectors in the
BORG family [20].
The septin protein controls the remodeling of actin during cell migration and may
therefore lead to the spread and invasion of metastatic cancer cells [21]. Septins help
to stabilize neonatal focal adhesions, which is one of the necessary steps for
tumor-related migration. The study found that the embryonic fibroblasts of SEPT9
knockout mice did migrate much slower than wild-type cells [22]. In addition,
SEPT9_i4 is also associated in the directionality of breast cancer cell MCF7 migration.
Further sustained directional migration depends on SEPT7 and BORG5, because it
can maintain proper actin filament organization [23]. Cell invasion and migration
require epithelial-mesenchymal transition (EMT), which encompasses cell processes
formation and alters the way cells interact with ECM. Studies have found that
knocking out SEPT9 can reverse EMT and reduce the spread, migration and invasion
of cancer cells [24]. In addition, SEPT1 is also associated with the spreading of
DJM-1 cells in the squamous cell carcinoma[24].
Septins are involved in tumor progression, including the formation of new blood
vessels and the transition of tumor cells into the tumor microenvironment. ECM
controls the expression of SEPT9 in endothelial cells through integrin signaling and
regulates the peripheral distribution of cell proliferation and actin assembly [25].
Concerning the migration of tumor-related fibroblasts, studies have shown that due to
the increased expression of the cross-linked protein BORG2, the cohesion between
septins and actin fibers increases [26]. This will lead to matrix remodeling, which will
help activate highly contracted cancer-related fibroblasts and promote the invasion of
cancer cell, angiogenesis, and tumor growth.
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4.4.4 Septin and microtubules
In some types of cells, septin filaments are co-paired with MTs. They compete with
the MT-stable protein MAP4 and reduce MT stability [27]. However, the relation
between septins and MT acetylation remains ambiguous. In dendritic cells, SEPT7 is
recorded interacting with tubulin deacetylase HDAC6 [28]. Additionally, septin
microfilaments interact with polyglutamylated MTs and facilitate the transport of
vesicles along these trajectories to sustain the polarity of MDCK cells [29].
Septins don’t only form a barrier to diffuse at the base of primary cilia, but also
associated with acetylated MTs in the axons of RPE-1 cells whose SEPT2/7/9
complex controls ciliary body length [30]. Loss of TTLL3 activity, a polysaccharide
acylation enzyme needed for a stable primary cilia genesis is closely related to the
development of colon cancer [31]. Similar to the study of septin microfilaments
recruiting tubulin polyglutaminase on MTs, axon-related septin may scaffold TTLL3
on cilia MTs because it is a part of the same enzyme family [32].
4.5 Septin with disease
4.5.1 Hereditary neuromuscular dystrophy (HNA)
HNA is a rare autosomal dominant inherited peripheral neuropathy characterized by
severe pain and weakness in the shoulders and/or arms, loss of feeling and atrophy of
the arm muscles. The patient usually recovers completely, but it may take weeks to
years. Genetic analysis of several HNA patients and their families identified mutations
in the SEPT9 gene [33]. To date, missense mutant subtypes R88W or S93F have been
found in some HNA families (the longest numbered SEPT9 subtype) [34]. In addition,
a repeat containing the SEPT9 gene was also detected, in which the length and
position of the repeated part SEPT9 were different. Interestingly, point mutations and
gene duplication occur in the N-terminal region shared by isomers 1, 2 and 3 of
SEPT9, but not 4 and 5, indicating the importance of this region for the onset of HNA
[35].
4.5.2 Male infertility
A group of patients infertile due to decreased sperm motility (azoospermia) showed
disintegration of ring and septin rings. Septins provide rigidity at the ring and acts as a
diffusion barrier to distinguish different parts of sperm. Specifically, SEPT4-deficient
mice can lead to loss of sperm motility, and studies have found that SEPT4 is essential
for the barrier between the midsection and the tail [36]. Although the loss of SEPT4
has been detected in infertile human males, the cause of SEPT4 loss remains to be
determined. The importance of SEPT4 and whether it provides cell rigidity or
diffusion barrier function needs further verification.
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4.5.3 Leukemia (MLL)
Septins are associated with various human MLL caused by the translocation of the
MLL oncogene to the septin gene locus [37]. MLL is located on chromosome 11q23,
a locus frequently involved in chromosomal translocations associated with leukemia
[38]. Although more than 60 different MLL gene translocations have been identified
so far, 5 of them involve members of the septin family, making it unlikely that this
will happen by accident. These translocations have caused a variety of acute
leukemias. The first described septin was fused to the MLL gene located on
chromosome 11, resulting in the chimeric protein containing the N-terminal region of
MLL linked to SEPT9 [39].
Other septins (SEPT2, SEPT5, SEPT6, and SEPT11) were later reported to have
experienced similar translocations and produced fusion proteins with MLL [40]. This
fusion protein is thought to lead to leukemia progression through excessive activation
of MLL, leading to unnecessary transcription of certain genes including members of
the HOX family [41, 42]. Septin's contribution to this activation is unclear, but may
involve their self-interacting properties that may lead to MLL dimerization [43]. In
addition, their association with membranes or other components of the cytoskeleton
can also play a role. Osaka et al. identified septins as the fusion partner for leukemia
MLL and found that in many cancer cells, SEPT2, 8, 9, and 11 are up-regulated, while
SEPT4 and 10 are down-regulated [44, 45].
4.5.4 Breast and ovarian cancer
The study found that the SEPT9 gene is closely related to breast and ovarian cancer.
The human SEPT9 locus has been identified as a hot allele in ovarian and breast
cancer. SEPT9 gene amplification can also be found in human and mouse breast
cancer cell lines [46].
4.5.5 Head and squamous sell carcinoma
Studies have found that strong expression of Sept9_i1 is linked to head and squamous
cell carcinoma poor prognosis. The frequency of methylation at the SEPT9 site
indicates that changes in the SEPT9 subtype may result in a malignant phenotype
[47].
4.5.6 Colorectal cancer (CRC)
The experiment found that SEPT9 is closely related to colorectal cancer. The decrease
in expression may be due to the reduction in the transcription frequency of the
promoter and its methylation of CpG islands [48]. Consistent with this, treatment of
cultured cells with demethylating agents resulted in increased levels of SEPT9 mRNA
and protein. This methylation change has recently been used to diagnose the colon
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cancer using blood-based SEPT9 gene promoter methylation detection [49]. Because
it is minimally invasive, it may have a higher participation rate than colonoscopy [50,
51]. These findings not only point out a new treatment method, but also provide a new,
effective and non-invasive diagnostic method for the diagnosis of colorectal cancer.
4.6 Aim of the study
4.6.1 SEPT6 drives proliferation, migration and invasion of hepatocellular
carcinoma through Hippo/YAP signaling pathway（Publication 1）
The gathered data proposes that the cytoskeleton proteins are essential for the
hepatocellular carcinoma tumorigenesis. Yet, the exact SEPT6 function in the
hepatocellular carcinoma is still unrevealed. In this study, by utilizing RT-PCR and
the western blot assay, we were able to identify the expression of SEPT6 in HCC cell
lines, as well as identifying the role of SEPT6 in proliferation, cell cycle progression,
invasion and migration of HCC by carrying out a gain- and loss- of function assays.
Furthermore, we examined the underlying mechanism focused on the Hippo signaling,
since that this pathway is crucial in progression and tumorigenesis of HCC. Our
findings demonstrated that the Hippo signaling is inhibited by the overexpression of
SEPT6, and that SEPT6 also affected the downstream effector YAP by stabilizing and
dephosphorylating it, and as a consequence, the active YAP is translocated to the
nucleus, so it could boost the Cyclin D1 and MMP2 transcription, leading to the
metastasis and growth of HCC. These gathered data as a whole have the potential to
yield a therapeutic intuition in the treatment of HCC. The data is published in
Publication1
4.6.2 Pretreatment with Zinc protects Kupffer cells following administration of
microbial products（Publication 2）
The severe liver fibrosis and the systemic inflammation can prompt a decline in the
concentration of the serum zinc. Nonetheless, the absence of any symptoms for zinc
deficiency leads it to be undetected in clinics. This research explored the relationship
between the serum zinc and the other indicators in CLD patients, in correlation with
the zinc protective mechanisms in SBP infections. And we found that: 1) there is a
direct correlation between deficient serum zinc concentrations and elevated MELD
scores and CRP levels in CLD patients , where 60 μg/dl is established to be the zinc
deficiency threshold; 2) There is a major LDH surge in both HSCs as well as KCs
induced by the bacterial products, yet, Only KCs but not HSCs, are preserved by the
zinc pretreatment; 3) Zinc pretreatment exhibited guarding features in KCs rather than
zinc posttreatment and these features are propagated through Myd88-MAPK-related
pathway; 4) The pretreatment of zinc decreases the TXB2 production in KCs
otherwise caused by bacterial stimulation. In a word, the levels of serum zinc seem to
be an important indicator in evaluating the severity of the CLD patients with infection
and liver fibrosis. The data were published in Publication 2.
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5 Summary
Publication 1:
SEPT6 drives proliferation, migration and invasion of hepatocellular carcinoma
through Hippo/YAP signaling pathway
The gathered data proposes that the cytoskeleton proteins are essential for the
hepatocellular carcinoma tumorigenesis. Septin 6 (SEPT6) is considered to be a
highly evolutionarily conserved GTP binding protein, which takes a crucial part in
regulating the biological behaviors of various cells, like actin dynamics, cell
migration and shape and more, Yet, the exact SEPT6 function in the Hippo signaling
and the hepatocellular carcinoma is still unrevealed. In this research, we revealed the
function of SEPT6 in hepatocellular carcinoma and the underlying
mechanism.Thereby, our study focused on the research of SEPT6 in hepatocellular
carcinoma and the underlying mechanism was discovered in this research.
In order to inspect the SEPT6 function in HCC we determined the SEPT6 expression
in 64 HCC sample pairs using qRT-PCR. Meanwhile,the expression of SEPT6 in both
HCC as well as the adjacent non-tumor tissues was traced by the western blot. he
correlation of SEPT6 expression with overall survival using Kaplan-Meier survival
analysis was then studied, which showed that the elevated SEPT6 expression level is
correlated with a poorer survival rate for HCC patients.Moreover, the SEPT6
expression in the database of GEPIA further confirmed the SEPT6 mRNA level
upregulation in the tissues of HCC. Subsequently,we utilized IHC staining in order to
examine the SEPT6 expression in the samples of HCC and non-tumor samples, we
discovered that the levels of SEPT6 expression were noticeably higher in the HCC
samples when compared to the non-tumor adjacent samples, while the expression of
SEPT6 protein was predominantly situated in the cytoplasm. Lastly, we assessed the
SEPT6 expression in the normal hepatocytes (Chang liver) as well as 5 HCC cell lines.
Both the WB and qRT-PCR results demonstrated that the expression of SEPT6 was
remarkably elevated in those characterized by large metastatic potential HCC cell
lines (MHCC-97H and HCC-LM3) when compared to the regular hepatocytes (Chang
liver). All these data pointed out that the expression of SEPT6 is upregulated in
human HCC and that it predicts bad prognosis
We also carried out a loss- and gain- of function assays in order to inspect the role of
SEPT6 in HCC proliferation and other cellular functions. The qRT-PCR and western
blot both confirmed the successful stable knockdown efficiency of SEPT6 in the cells
of MHCC-97H as well as the overexpression efficiency in Huh7 cells. We then carried
out the CCK-8 assays in order to assess the function of SEPT6 in the proliferation of
cells. We observed the cell cycle distribution via FACS in order to check if the
proliferation is regulated by SEPT6 via altering the cell cycle transition. The findings
proposed that SEPT6 advanced the transition of G1/S cell cycle in HCC cells.
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Consequently, we recognized the cyclin D1 and cyclinE1 expression, that is
substantially linked to transition of G1/S cell cycle. Afterwards, we carried out
Transwell assays and were able to recognize the MMP2 and MMP9 expression via
qRT-PCR and WB to examine both the HCC cells invasion and migration capabilities
after both the overexpression and the knockdown. Lastly, we discovered that the
overexpression of SEPT6 in vitro significantly prompted the HCC proliferation, cell
cycle migration, invasion, and progression, while the SEPT6 suppression imposed the
counter effects on HCC cell lines. Hence, we recognized SEPT6 as an oncogene in
HCC, contrasting to its function in the prostate cancer.
Afterwards, the underlying mechanism why SEPT6 acts as an oncogene was explored.
The Hippo signaling as the pathway plays vital role in HCC tumorigenesis and
progression was mainly studied. T Our findings demonstrated that the overexpression
of SEPT6 inhibited the Hippo signaling pathway as well as stabilizing and
dephosphorylating the downstream effector YAP, as a consequence, the active YAP,
boosted the Cyclin D1 and MMP2 transcription when it is translocated to the nucleus,
leading to the metastasis and growth of HCC. Moreover, the YAP knockdown reduced
the function of SEPT6 in the progression of HCC, whilst the overexpression of YAP
preserved the suppressing function of SEPT6 downregulation. Accordingly, SEPT6
applied its oncogenic abilities in HCC by regulating the Hippo/YAP signaling
pathway.
To conclude, our research proposed that SEPT6 is upregulated in HCC and that it acts
as oncogene in the progression of HCC. We also documented that SEPT6 is
prompting the HCC proliferation, cell cycle migration, invasion and progression,
where is at least via an innovative SEPT6/Hippo/YAP axis. All in all, our data
displayed that SEPT6 plays an oncogenic role in HCC, that can administer a
therapeutic target in the treatment of HCC.
Publication 2:
Pretreatment with Zinc protects Kupffer cells following administration of
microbial products
Zinc is a crucial trace metal to maintain human functions, and it is vital in about 300
enzymes for their formation and functionality. Moreover, zinc exhibits antioxidizing
and antiapoptotic abilities, and it is widely used in anti-bacterial pathogens studies.
The serum zinc levels can be severely hindered by systemic inflammation and severe
fibrosis, on the other hand, the supplementation of patients by zinc is shown to
enhance their Chronic liver disease (CLD) prognosis. Even though that the zinc
associated medications proved its vitality, there has been no universal agreement on
the dosage, timing and the mechanism of the effects yet. Bacterial isolates collected
from SBP patients isolated strains are used to treat the human primary liver
non-parenchymal cells such as HSCs, KCs and sinusoidal endothelial cells (SECs) in
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this research, and the clinical data gathered throughout 2016 to 2019 was aggregated,
in order to inspect the role of zinc in suppressing the microbial infections as well as
the clinical application of zinc for CLD patients.
According to serum zinc levels, 149 CLD patients were split to three groups. The
markers related to infection and fibrosis were compared. The findings showed a major
inverse correlation between serum zinc levels and CRP and a major direct correlation
between serum zinc and albumin in the both groups.
In in-vitro experiments, the human liver non parenchymal cells were triggered by
microbial isolates extracted from patients, and in certain cases the solution of zinc
sulfate was added. By comparing the effect of zinc by LDH and thromboxane A2
(TXA2) levels in the cell supernatant, the study intended to explore the clinical effects
of the serum zinc in CLD patients as well as its protective effects in in-vitro
experiments. We found that zinc pretreatment could protect the injury of bacterial
stimulation in TMCs. Patients with deficient serum zinc levels showed more
C-reactive protein (CRP), GGT, INR, total bilirubin, MELD score as well as lower
albumin levels compared to other groups. There is a prevalent correlation between
serum zinc with CRP and Albumin in both the groups with low and normal zinc levels,
LDH levels were surged in Kupffer cells (KCs) as well as stellate cells by bacterial
isolates, However, it did not show any impact on the sinusoidal endothelial cells,
where the pretreatment by zinc only protected the KCs.
Finally, we investigated the potential associated pathway for zinc protection by
RT-qPCR, and found that Myd88 related signaling pathway was vital for the
protecting zinc pretreatment impacts in bacterial-induced injury in KCs, and reduced
production of thromboxane A2 was due to decreased gene expression of Myd88,
MAPK and NF-kB.
In summary, the levels of serum zinc show a high probability of being a worthy
weapon in evaluating the mass of the infection and liver fibrosis in CLD patients.
Moreover, the findings reinforced our comprehension of the supplementation by zinc
as a viable antimicrobial ally where the pretreatment by zinc is shown to constrain
inflammation through suppressing Myd88-MAPK-NF-κB pathway activation in KCs,
and TXA2 as an important player.
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6 Zusammenfassung
Veröffentlichung 1:
SEPT6 fördert die Tumorprogression über den Hippo/YAP-Signalweg beim
hepatozellulären Karzinom
Akkumulative Studien haben gezeigt, dass Zytoskelettproteine eine wichtige Rolle bei
der Tumorentstehung des Leberzellkarzinoms spielen. Septin 6 (SEPT6) ist ein
hochgradig evolutionär konserviertes GTP-bindendes Protein, das eine bedeutende
Rolle bei der Regulierung verschiedener zellbiologischer Verhaltensweisen wie
Aktindynamik, Zellform und Zellmigration usw. spielt. Die Rolle von SEPT6 bei der
Entwicklung des hepatozellulären Karzinoms (HCC) und der Hippo-Signalweg ist
jedoch noch unbekannt. In dieser Studie haben wir die Rolle von SEPT6 beim
hepatozellulären Karzinom und den zugrunde liegenden Mechanismus aufgedeckt.
Um die Rolle von SEPT6 auf HCC zu untersuchen, haben wir die Expression von
SEPT6 in 30 Paaren von HCC-Proben mittels qRT-PCR gemessen. Die Expression
von SEPT6 im HCC und in angrenzenden Nicht-Tumorgeweben wurde ebenfalls
durch Western Blot bestätigt. Wir analysierten dann die Expression von SEPT6 in der
GEPIA-Datenbank, wobei das Ergebnis auch die Hochregulation des
SEPT6-mRNA-Spiegels in HCC-Geweben bestätigte. Als nächstes haben wir die
Expression von SEPT6 in zwei normalen Leberzelllinien und mehreren
HCC-Zelllinien gemessen. Zusammengenommen deuten diese Ergebnisse darauf hin,
dass die SEPT6-Expression in HCC-Geweben und Zelllinien mit hochgradig
metastatischem Potenzial hochreguliert ist.
Um die Rolle von SEPT6 bei der zellulären Funktion des HCC wie HCC-Proliferation,
Zellzyklusprogression, Migration und Invasion zu untersuchen, haben wir
Funktionsverlust- und Gewinn-Assays durchgeführt. Der erfolgreiche stabile
SEPT6-Knockdown in MHCC-97H-Zellen und die Überexpression in Huh7-Zellen
wurden durch qRT-PCR und Western Blot bestätigt. Um die Rolle von SEPT6 bei der
Zellproliferation zu untersuchen, führten wir die CCK-8-Tests durch. Um zu
untersuchen, ob SEPT6 die Proliferation durch Beeinflussung des
Zellzyklusübergangs reguliert, haben wir die Zellzyklusverteilung mittels FACS
nachgewiesen. Die Daten legten nahe, dass SEPT6 den G1/S-Zellzyklusübergang in
HCC-Zellen fördert. In der Folge entdeckten wir die Expression von Cyclin D1 und
Cyclin E1, die signifikant mit dem G1/S-Zellzyklusübergang zusammenhängen. Wir
führten dann Transwell-Assays durch und untersuchten die Expression von MMP2
und MMP9 mittels qRT-PCR und WB, um die Migrations- und Invasionsfähigkeit von
HCC-Zellen nach dem Knockdown oder der Überexpression von SEPT6 zu beurteilen.
Schließlich fanden wir in vitro heraus, dass die Überexpression von SEPT6 die
Proliferation, Zellzyklusprogression, Migration und Invasion von HCC-Zellen
förderte, während die Unterdrückung von SEPT6 die entgegengesetzten
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Auswirkungen auf die HCC-Zelllinien hatte. Daher gehen wir davon aus, dass SEPT6
beim HCC als Onkogen fumgiert, was im Gegensatz zu seiner Rolle bei Prostatakrebs
steht.
Als nächstes untersuchten wir den zugrunde liegenden Mechanismus, warum SEPT6
als Onkogen wirkt. Wir konzentrierten uns hauptsächlich auf den Hippo-Signalweg,
da dieser eine entscheidende Rolle bei der Tumorentstehung und -progression des
HCC spielt. Unsere Daten bewiesen, dass die SEPT6-Überexpression den
Hippo-Signalweg inaktivierte, den nachgeschalteten Effektor YAP stabilisierte,
woraufhin das aktive YAP in den Zellkern translozierte, wo es die Transkription von
Cyclin D1 und MMP2 förderte, was zu HCC-Wachstum und Metastasierung führte.
Darüber hinaus verringerte der Knockdown von YAP die günstige Rolle von SEPT6
bei der HCC-Progression, während die YAP-Überexpression die hemmende Rolle der
SEPT6-Abwärtsregulierung rettete. Mechanistisch gesehen übte SEPT6 seine
onkogene Rolle beim HCC aus, indem es den Hippo /YAP-Signalweg regulierte.
Zusammenfassend lässt sich sagen, dass unsere Studie darauf hinweist, dass SEPT6
im HCC hochreguliert ist und als Onkogen in der HCC-Progression wirkt. Wir
definierten, dass SEPT6 die HCC-Proliferation, die Migration und die Invasion im
Zellzyklus fördert, was zumindest durch eine neue SEPT6/ Hippo /YAP-Achse
erreicht wird. Insgesamt zeigten unsere Ergebnisse eine onkogene Rolle von SEPT6
beim HCC, die ein therapeutisches Interventionsziel für die Behandlung des HCC
darstellen könnte.
20
Veröffentlichung 2:
Vorbehandlung mit Zink schützt Kupfferzellen nach Verabreichung von
mikrobiellen Produkten
Zink ist ein essentielles Spurenmetall im menschlichen Körper und spielt eine
wichtige Rolle bei der Zusammensetzung und Funktion von mehr als 300 Enzymen.
Zink hat antioxidative und antiapoptotische Wirkungen und wird häufig in Studien
gegen bakterielle Krankheitserreger verwendet. Systemische Entzündungen und
schwere Fibrosen können zu einer signifikanten Senkung des Zinkspiegels im Serum
führen, während eine Zinksupplementierung die Prognose von Patienten mit
chronischer Lebererkrankung (CLD) verbessern könnte. Obwohl über zinkbezogene
Behandlungen als neue antibakterielle Waffen berichtet wurde, gibt es noch keinen
Konsens über die Dosierung, den Zeitpunkt und die Mechanismen, die für solche
Effekte verantwortlich sind. In dieser Studie wurden humane primäre
nicht-parenchymale Leberzellen [einschließlich KCs, HSZs und sinusoidale
Endothelzellen (SECs)] mit Bakterienisolaten behandelt, die aus Stämmen von
SBP-Patienten isoliert wurden. Durch die Kombination der von uns von 2016 bis
2019 gesammelten klinischen Daten wollten wir den Mechanismus von Zink zur
Verhinderung mikrobieller Infektionen und seine klinische Anwendung bei Patienten
mit CLD untersuchen.
Nach den Serum-Zinkspiegeln wurden 149 CLD-Patienten in 3 Gruppen eingeteilt.
Die mit der Infektion und Fibrose verbundenen Marker wurden verglichen. Die Daten
zeigten eine signifikant negative Korrelation zwischen den Serum-Zinkspiegeln und
dem CRP und eine signifikant positive Korrelation zwischen Serum-Zink und
Albumin in beiden Gruppen.
In In-vitro-Experimenten wurden mikrobielle Isolate von Patienten verwendet, um
nicht-parenchymale Zellen der menschlichen Leber zu stimulieren, und in bestimmten
Experimenten wurde die Zinksulfatlösung hinzugefügt. Durch den Vergleich der
Wirkung von Zink durch LDH- und Thromboxan-A2-Spiegel im Zellüberstand
wollten wir die klinische Anwendung von Serum-Zink bei Patienten mit CLD und
seinen anti-infektiven Mechanismus in in-vitro-Studien untersuchen. Wir fanden
heraus, dass eine Vorbehandlung mit Zink die Verletzung der bakteriellen Stimulation
bei TMCs schützen könnte. Patienten mit niedrigen Serumzinkwerten zeigten im
Vergleich zu anderen Gruppen höhere C-reaktive Proteine (CRP), GGT, INR,
Gesamtbilirubin, MELD-Score und niedrigere Albuminwerte. CRP und Albumin
waren sowohl in den Niedrig- als auch in den Normalzinkgruppen signifikant mit dem
Serumzink korreliert. Bakterienisolate erhöhten die LDH-Spiegel in Kupfferzellen
(KCs) und hepatischen Sternzellen signifikant, hatten aber keinen Einfluss auf
Sinusendothelzellen, während die Vorbehandlung mit Zink zwar die KCs, nicht aber
die hepatischen Sternzellen schützte.
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Schließlich untersuchten wir den möglichen verwandten Pfad für den Zinkschutz
durch RT-qPCR und stellten fest, dass der Myd88-verwandte Pfad für die schützende
Wirkung der Zink-Vorbehandlung bei bakteriell induzierten Verletzungen in KCs
wesentlich ist, und dass die verminderte Produktion von Thromboxan A2 auf die
verminderte Genexpression von Myd88, MAPK und NF-kB zurückzuführen ist.
Zusammenfassend lässt sich sagen, dass die Serum-Zink-Konzentration ein wertvoller
Marker für die Beurteilung des Schweregrades der Infektion und der Leberfibrose bei
Patienten mit CLD sein kann. Darüber hinaus vertiefen unsere Ergebnisse unser
Verständnis der Zinksupplementierung als antimikrobielle Waffe: Die Vorbehandlung
mit Zink reduziert die Entzündung durch Hemmung der Aktivierung des
Myd88-MAPK-NF-κB-Signalwegs bei KCs und TXA2 als wichtigen Akteur.
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